Skip to content

The impact of percutaneous transoral vagus nerve stimulation during the perioperative period on postoperative recovery quality after hip arthroplasty in elderly patients: a randomized, double-blind, sham-stimulation controlled trial

The impact of percutaneous transoral vagus nerve stimulation during the perioperative period on postoperative recovery quality after hip arthroplasty in elderly patients: a randomized, double-blind, sham-stimulation controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128292
Enrollment
Unknown
Registered
2026-07-17
Start date
2026-07-17
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fractures requiring hip replacement

Interventions

Stimulation Group:Percutaneous auricular vagus nerve stimulation
Sham stimulation group:Percutaneous auricular vagus nerve Sham stimulation

Sponsors

The Affiliated Hospital of Yangzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years; 2. ASA classification levels I–III; 3. Scheduled for elective semi-total or total hip arthroplasty; 4. The patient voluntarily participates and signs an informed consent form, understands the study protocol and assessment scales, and has effective communication skills.

Exclusion criteria

Exclusion criteria: 1. Presence of a clear neurological or psychiatric disorder in the medical history (e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, etc.), or ongoing use of corresponding therapeutic medications; 2. Preoperative cognitive impairment (MMSE score <23); 3. Lesions such as dermatitis, rash, infection, or trauma on the left auricle; 4. Treatment-resistant arrhythmia, preoperative resting heart rate <50 beats/min, sick sinus syndrome, second-degree or higher atrioventricular block, or implantation of a cardiac pacemaker; 5. Recent (within 1 month) use of cholinergic drugs, anticholinergic drugs, or glucocorticoids; 6. History of neurosurgical surgery, severe hearing or visual impairment, opioid abuse, participation in other clinical trials within the past 30 days, or illiteracy; 7. Other circumstances deemed unsuitable by the investigator.

Design outcomes

Primary

MeasureTime frame
QoR-15 Total Score (Range: 0–150 points);

Countries

China

Contacts

Public ContactWang Maohua

The Affiliated Hospital of Yangzhou University

wmhyz002@126.com+86 13952590032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026